Bayer HealthCare chief Fibig departs for CEO post; China fines J&J, B&L for price-fixing;

@FiercePharma: ICYMI: Yesterday's full issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@TracyStaton: ICYMI, FiercePharma's top weekend news: FDA-nixed diabetes med from Lilly, Boehringer faces rough path to stardom. Article | Follow @TracyStaton

@CarlyHFierce: Our newest special report is here! Top 10 best-selling cancer drugs of 2013, just in time for #ASCO14. Feature | Follow @CarlyHFierce

> Bayer HealthCare President Andreas Fibig is jumping ship to take on the CEO job at International Flavors & Fragrances; Bayer says a replacement will be named in a few days. Report

> China fined Johnson & Johnson ($JNJ) and the Valeant Pharmaceuticals ($VRX) unit Bausch & Lomb for alleged price-fixing on eye-care products. Report

> U.S. traders' ignorance of U.K. takeover rules spawned confusion amid Pfizer's ($PFE) $117 billion play for AstraZeneca ($AZN). Report

> Pittsburgh-based generics maker Mylan ($MYL) rolled out its version of Malarone, the GlaxoSmithKline ($GSK) malaria treatment, in the U.S. Release

> Merck Serono launched a web-based software system that can track patients' injections of its multiple sclerosis treatment Rebif. Report

Medical Device News

@FierceMedDev: St. Jude to take over CardioMEMS following FDA approval. News | Follow @FierceMedDev

@VarunSaxena2: Who wants to read the UK Takeover Code with me? Wondering if the FT story counts as a "statement." More (PDF) | Follow @VarunSaxena2

@MichaelGFierce: ICYMI yesterday from FierceDrugDelivery: 'Nanodaisies' carry two cancer drugs and protect them in the bloodstream. Story | Follow @MichaelGFierce

@EmilyWFierce: Top 10 best-selling cancer drugs brought in between $1.7B and $7.8B in 2013, with Roche's Rituxan leading the pack. More | Follow @EmilyWFierce

> FDA clears nonsurgical treatment for male urinary and fecal incontinence. More

> Stryker CEO clears the air regarding Smith & Nephew deal. Story

> Medtronic shells out $9.9M to settle physician kickback claims. Article

Biotech News

@FierceBiotech: Tune in today for an #ASCO14 chat w/ @JohnCFierce & @PennMedicine's David Porter at 3:30 EST. More info | Follow @FierceBiotech

@JohnCFierce: So now it's $GSK that's supposed to want to buy $ARIA? Any bets on the next big pharma in this particular rumor mill? | Follow @JohnCFierce

@DamianFierce: From BMO's survey of $AGN shareholders: How will $AGN's business be in 3 years if $VRX buys it? Table | Follow @DamianFierce

@EmilyMFierce: Popular at : #Antisense compound may provide new #Alzheimers treatment. Story | Follow @EmilyMFierce

> Trimel wins FDA approval for its 'low-T' nasal gel. Item

> ASCO: Big Four immuno-oncology players wager $1.3B on next-gen cancer drugs. Report

> Rodin bags a $12.9M A round to think big about CNS therapies. News

> Lilly steps out of its comfort zone, backs an international biotech fund. Article

Pharma Manufacturing News

> Actavis commits $48M to revitalizing Puerto Rico plants. More

> Hospira plans $120M investment in Kansas facility. Item

> Lilly, Merck juggle cost and complexity in manufacturing strategies. Report

> FDA circles Wockhardt's Illinois plant as earlier sanctions slash sales. More

> Hikma lined up as potential buyer of troubled Ben Venue plant. Story

> FDA puts improved generic evaluations on $50M regulatory wishlist. Article

Vaccines News

> Pfizer teams up to lift adult vaccination rates--and Prevnar sales, too. News

> Study: Only 50% of Canadian healthcare workers are vaccinated. Story

> ASCO preview: What's the outlook for cancer vaccines? Report

> Study: Moral concerns lead barriers to Gardasil uptake in college freshmen. More

> Inovio sells off animal health assets to zero in on vaccines. Item

And Finally... The skeptical and cynical may be at higher risk for dementia. Report